BOULDER – BioLineRx Ltd., a biopharmaceutical company based in Jerusalem, announced Monday that it has licensed from the University of Colorado a compound for the treatment of neuropathic pain.
Terms of the licensing agreement were not disclosed.
The compound, BL-1110, also can be developed for the treatment of scleroderma, an autoimmune disease characterized by a hardening and tightening of the skin and connective tissues.
Neuropathic pain is caused by damage or diseases affecting the nervous system, and doesn’t typically respond well to regular painkillers. In pre-clinical studies in rats, BL-1110 has been shown to enhance the effects of morphine.
Psychology and neuroscience professor Linda Watkins and chemistry professor Hang Hubert Yin, both from CU-Boulder, developed BL-1110.
BioLineRx (Nasdaq: BLRX) is a clinical-stage biopharmaceutical company focused on licensing and developing promising therapeutic
Sponsor Generated Content
How do the revised rules in the Bipartisan Budget Act of 2015 affect you and your business?